electroCore, Inc. announced its non-invasive vagus nerve stimulation therapy, gammaCore, has been awarded a five-year Federal Supply Schedule Medical Equipment and Supply contract which will make gammaCore available in January to the over 21 million patients managed within the Department of Veteran’s Affairs, Department of Defense, Bureau of Prisons, Indian Health Services and Public Health Services. gammaCoreTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore is indicated for: Adjunctive use for the preventive treatment of cluster headache in adult patients. The acute treatment of pain associated with episodic cluster headache in adult patients. The acute treatment of pain associated with migraine headache in adult patients. The safety and effectiveness of gammaCore (nVNS) have not been established in the acute treatment of chronic cluster headache gammaCore has not been shown to be effective for the preventive treatment of migraine headache The long-term effects of the chronic use of gammaCore have not been evaluated Safety and efficacy of gammaCore have not been evaluated in the following patients, and therefore it is NOT indicated for: Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device Patients diagnosed with narrowing of the arteries (carotid atherosclerosis) Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy) Pediatric patients, Pregnant women, Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia, Patients should not use gammaCore if they: Have a metallic device such as a stent, bone plate, or bone screw implanted at or near their neck Are using another device at the same time.